IRON Stock: Price, Earnings History and SEC Filings
Disc Medicine, Inc. (IRON) last traded at $80.84, down 2.41% on the latest session and up 23.5% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.54 against an analyst estimate of $-1.58, a beat of 2.5%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
IRON earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 30, 2026 | $-1.54 | $-1.58 | +2.53% |
| Mar 2026 | May 5, 2026 | $-1.65 | $-1.55 | -6.45% |
| Dec 2025 | Feb 26, 2026 | $-1.62 | $-1.69 | +4.14% |
| Sep 2025 | Nov 6, 2025 | $-1.77 | $-1.48 | -19.59% |
IRON beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How IRON reacts to earnings
Across its last 8 earnings releases, IRON moved 2.3% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-22 | After close | -0.69% |
| 2026-07-30 | Before open | +7.52% |
| 2026-05-05 | Before open | -0.07% |
| 2026-02-26 | Before open | +1.52% |
| 2026-01-12 | Before open | +1.13% |
| 2025-11-06 | Before open | -1.48% |
| 2025-10-20 | Before open | -3.08% |
| 2025-08-07 | Before open | -3.27% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
IRON financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | – | -$212M | -$181M | – | $-6.01 |
| 2024 | – | -$109M | -$94M | – | $-3.96 |
| 2023 | – | -$76M | -$74M | – | $-3.42 |
| 2022 | – | -$47M | -$42M | – | $-45.05 |
| 2021 | – | -$36M | -$28M | – | $-40.95 |
| 2020 | – | -$41M | -$33M | – | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for IRON
- 8-K · Oct 22, 2026Material agreement, Results of operations, Other events
- 424B5 · Oct 21, 2026
- 424B5 · Oct 20, 2026
- 8-K · Oct 19, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Sep 10, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 10-Q · Jul 30, 2026
- 8-K · Jul 30, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 30, 2026Material agreement, New financial obligation
- 8-K · Jun 24, 2026Shareholder vote
- 10-Q · May 5, 2026
Insider filing activity
IRON insiders filed 9 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
IRON news
- Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal StudyOct 22, 2026 · finance.yahoo.com
- Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common StockOct 21, 2026 · finance.yahoo.com
- A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on MondayOct 20, 2026 · finance.yahoo.com
- Disc Medicine Stock Jumps After Phase 3 Trial Success And FDA Refiling PlanOct 20, 2026 · finance.yahoo.com
- Disc Medicine (IRON) APOLLO Win Puts Its Valuation Discount Back In FocusOct 19, 2026 · finance.yahoo.com
- Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded WarrantsOct 19, 2026 · finance.yahoo.com
- What Could Disc Medicine (IRON) Reveal From Its Phase 3 APOLLO Trial?Oct 19, 2026 · finance.yahoo.com
- Disc’s once-spurned rare disease drug to get a second chance at approvalOct 19, 2026 · biopharmadive.com
About Disc Medicine, Inc.
Disc Medicine, Inc. (IRON) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. Its fiscal year ends in December.